MeiraGTx Holdings PLC (MGTX)vsModerna Inc (MRNA)
MGTX
MeiraGTx Holdings PLC
$9.71
-0.46%
HEALTHCARE · Cap: $884.56M
MRNA
Moderna Inc
$222.76
+4.01%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 461% more annual revenue ($2.23B vs $397.50M). MGTX leads profitability with a 19.9% profit margin vs -141.4%. MGTX earns a higher WallStSmart Score of 61/100 (C+).
MGTX
Buy61
out of 100
Grade: C+
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MGTX.
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$222.76
$88.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Strong operational efficiency at 76.0%
Revenue surging 8609.0% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 13.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MGTX
The strongest argument for MGTX centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 19.9% and operating margin at 76.0%. Revenue growth of 8609.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MGTX
The primary concerns for MGTX are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MGTX profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MGTX carries more volatility with a beta of 1.35 — expect wider price swings.
MGTX is growing revenue faster at 8609.0% — sustainability is the question.
MGTX generates stronger free cash flow (-41M), providing more financial flexibility.
Bottom Line
MGTX scores higher overall (61/100 vs 21/100), backed by strong 19.9% margins and 8609.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MeiraGTx Holdings PLC
HEALTHCARE · BIOTECHNOLOGY · USA
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?